Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

BioIntellisense

Explore full profile

Continuous health monitoring and clinical intelligence company with medical-grade wearable devices and Data-as-a-Service

Golden, United StatesFounded 2018Health Tech & Medtech
Valuation $250–500M Last recorded · 2021
Revenue $10–50M Latest reported FY
Headcount <100 Current team size
Total funding $50–100M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for BioIntellisense and the history behind them.

About BioIntellisense

BioIntelliSense is a medical technology startup that specializes in remote patient monitoring. The company offers a wearable device, the BioButton, which provides continuous, medical-grade monitoring of a patient's vital signs. This device is designed to be comfortable, discreet, and easy to use, making it an attractive option for patients who require ongoing monitoring but prefer to stay at home. The BioButton collects data that can be analyzed to detect early signs of health issues, enabling proactive medical intervention.

BioIntelliSense primarily serves hospitals, health systems, provider organizations, and payors in the U.S. and select global markets. The company's business model revolves around selling its wearable devices and providing data analytics services. By offering a cost-effective solution for continuous monitoring, BioIntelliSense can help healthcare providers improve patient care while reducing costs associated with hospital stays and emergency interventions.

The company has been recognized for its innovative approach, winning the MedTech Breakthrough Award in 2023 for Best Overall Medical Device Company. It has also established strategic partnerships with other healthcare organizations, such as Ardent Health Services, to expand its reach and impact.

The company is led by Dr. Mault, a seasoned executive with over 35 years of experience in health IT and medical device industry. He has a strong track record of innovation, with over 80 issued and pending patents to his name.

Source: Dealroom company data

At a glance

Founded
2018
Headquarters
Golden, United States
Sector
Health Tech & Medtech
Power Law
Colt$25–100M revenue

Investors

16 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A9 investors entered at this stage

  • Fresenius Medical Care Balboa II
  • Jonathan Weiner
  • CU Healthcare Innovation Fund
  • 7wire Ventures
  • Chimera
  • Triple Tree Capital Partners
  • UCHealth
  • James Murren
  • Royal Philips

Series B and later7 investors entered at this stage

  • Royal Philips
  • James Murren
  • Triple Tree Capital Partners
  • Chimera
  • 7wire Ventures
  • UCHealth
  • CU Healthcare Innovation Fund
Employees mapped 87 incl. 4 AI specialists
Founders Hidden — book a demo/100 quality score
Key operators 8 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
7 countries with
team presence
🇺🇸 United States83.1%
🇵🇭 Philippines9.1%
🇦🇪 United Arab Emirates2.6%
🇵🇪 Peru1.3%
🇨🇦 Canada1.3%
Top 5 of 7 shown
Web traffic by country
2.9K monthly visits
across markets
🇺🇸 United States89.7%
🇮🇳 India10.3%
Top 2 markets shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about BioIntellisense on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See BioIntellisense on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.